Citizens JMP analyst Reni Benjamin downgraded Blueprint Medicines (BPMC) to Market Perform from Outperform without a price target given the proposed acquisition by Sanofi (SNY). Shareholders should vote in favor of this acquisition as the offer is fair and competing bids are unlikely, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BPMC:
- Blueprint Medicines downgraded to Hold from Buy at TD Cowen
- Blueprint downgraded to Peer Perform from Outperform at Wolfe Research
- Blueprint Medicines downgraded to Neutral from Overweight at JPMorgan
- Blueprint Medicines downgraded to Perform from Outperform at Oppenheimer
- Blueprint Medicines downgraded to Sector Perform from Outperform at Scotiabank